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The ability to better understand and predict 
the onset of antibiotic resistance to new drugs 
is needed. Antibiotic resistance has become 
an emerging issue of concern, and there 
are emphases to minimize its escalation. 
The number of cases of antibiotic resistant 
infections is increasing, as are the numbers 
of multidrug resistant bacteria. As a result, 
more antibiotics are becoming of limited use 
and previous attempts to tackle the resist-
ance problem remain relatively ineffective. 
If we can more effectively anticipate how 
and when resistance is likely to arise, we can 
better manage drug use and perhaps extend 
efficacy of chemical treatment.
Hernández et al. (2011) discuss how 
quinolones were introduced as novel anti-
biotics, and being synthetic, there were no 
pre-existing resistance mechanisms antici-
pated. The logic was that if the antibiotics 
were not synthesized by bacteria (or derived 
from a bacterially synthesized antibiotic), 
there would be fewer resistance genes har-
bored in nature. As such, it was originally 
anticipated resistance would arise solely 
from mutations.
There are four types of resistance mech-
anisms: modification of the antibiotic, 
modification of the target site, efflux of the 
drug, and reduced permeability of the cell. 
Natural antibiotics would be anticipated to 
have resistance genes falling into some, if 
not all of these categories. Semi-synthetic 
antibiotics are merely modified natural 
antibiotics, so they attack the same targets 
and have similar molecular structures as 
their predecessors. Therefore, it would be 
expected that they would be susceptible to 
the same resistance mechanisms as those for 
natural antibiotics. Synthetic drugs, such as 
quinolones, do not have a similar structure 
to any pre-existing drugs, so the only type 
Resistance to quinolones was conferred by 
drug efflux pumps, target protecting pro-
teins, and quinolone modifying enzymes. 
In particular, mechanisms for target protec-
tion, and drug modification are of particu-
lar concern as there is no explanation how 
these mechanisms arose.
Qnr is a quinolone resistance gene that 
originated in aquatic bacteria, which made its 
way into clinical isolates (probably as a result 
of quinolones being used in fish farming). 
Environmental bacteria are diverse; despite 
advances in metagenomics, many bacteria 
and functional genes have yet to be identified. 
Sources of resistance may simply be (at this 
time) unknown. Cfr originated on plasmids 
in bacterial strains associated with animals 
[possibly swine (Kehrenberg et al., 2008)] but 
managed to make it into the chromosome 
of human bacterial strains (Toh et al., 2007) 
despite linezolid having never been used 
agriculturally. Hernández et al. (2011) have 
already outlined the shortcomings in fore-
casting quinolone resistance. The inability to 
predict quinolone inactivating enzymes was 
based on the fact that there were no known 
enzyme homologs. Proteins with different 
primary structures and functions may in 
fact have similar quaternary structures, so the 
appearance of deactivating enzymes should 
not be written off as highly unlikely.
Currently, new oxazolidinones are being 
developed for eventual clinical use (Prasad, 
2007). The examples of both quinolone and 
linezolid resistance development indicate 
that better models for the prediction of anti-
biotic resistance need to be developed, with 
additional parameters being taken into con-
sideration. Certainly what Hernández et al. 
(2011) presented is not an isolated case. If 
we are better able to predict resistance we 
may be able to extend the shelf life of these 
new drugs longer than their predecessors.
Resistance to new drugs happens, despite 
drug novelty. We should consider bacterial 
diversity, possible exposure to and mobility 
of genetic traits, and other factor that may 
exacerbate mutagenesis and gene dissemi-
nation, such as environmental pollution. 
We can only hope that by limiting external 
of resistance that they could be  susceptible 
to is modification of the drug site, as it 
may already be the target of another class 
of antibiotics.
The same rationale was applied to oxa-
zolidinones, a new class of antibiotics dis-
covered in the 1980s (Livermore, 2003) with 
the first drug, linezolid, released to market 
in 2000. The drug’s mechanism of action 
involves the inhibition of the formation of 
the 70S-ribosome complex, preventing pro-
tein synthesis. As bacteria have more than 
one 23S-rRNA gene, it was thought that 
resistance arising via mutations would be 
less likely to occur (Meka and Gold, 2004). 
As a result of this, linezolid was earmarked 
as a drug of last resort against methicillin 
resistant Staphylococcus aureus (MRSA) and 
vancomycin resistant Enterococci (VRE).
Resistance to linezolid appeared very 
quickly. By 2001, resistant strains of MRSA 
and VRE were observed (Taubes, 2008). 
Linezolid is the only drug in its class 
approved for use, and it was highly surpris-
ing when resistance in the form of the cfr 
gene appeared (Mendes et al., 2008; Morales 
et al., 2010). Cfr confers resistance to several 
drugs – phenicols, lincosamides, oxazolidi-
nones, pleuromutilins, and streptogramin A 
(PhLOPSA). While these drugs are chemically 
unrelated, cfr causes methylation of a nucleo-
tide that is in the region of the ribosome these 
drugs bind (Long et al., 2006). This mutation 
inhibits the drug–target interaction render-
ing the antibiotics ineffective.
It could be argued, with many drugs 
designed to attack the same target, resistance 
to linezolid should not have been surpris-
ing. As previously mentioned, modification 
of the drug site resistance is not unexpected 
with synthetic drugs. However, linezolid has 
a unique interaction with the ribosome, 
so it was thought it would overcome the 
resistance issues faced by other drugs classes 
(Long et al., 2006; Toh et al., 2007). Judging 
by how quickly resistance appeared, clearly 
this assumption was incorrect.
When resistance to quinolones appeared, 
it became apparent that it was caused by 
more than just the anticipated mutations. 
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 factors, such as these, the resistance gene 
reservoir may eventually decline and pro-
long drug efficacy.
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